Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 15, 2011

Biosearch Licenses Probes to Intelligent Medical Devices

  • Biosearch Technologies licensed access to patents for its Black Hole Quencher® (BHQ) series of dark quenchers and its CAL Fluor® and Quasar® dyes to Intelligent Medical Devices (IMDx), a developer and manufacturer of molecular tests. In addition, Biosearch will manufacture cGMP oligonucleotides for IMDx for use in its in vitro diagnostics.  

    Biosearch was awarded patents and continuations beginning in 2006 for its BHQ quencher technology. It is used in a variety of fluorescence quenching applications including multiplex real-time, quantitative PCR, and assays requiring FRET-quenched peptides.

    In 2008, Biosearch was awarded a patent for the CAL Fluor series of fluorescent dyes, developed for the purpose of modifying synthetic DNA to enhance its detectability. The Quasar dyes are covered by a patent application filed by Biosearch with the U.S. Patent & Trademark Office.

    Founded in 1993, Biosearch designs, develops, and manufactures oligonucleotide-based tools included in custom-synthesized probe formats for real-time, quantitative PCR and other genomic-based applications.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »